Purpose: To evaluate the effectiveness and safety of a new presbyopia-correcting intraocular lens (IOL) with a nondiffractive design, DFT015, compared with an aspheric monofocal IOL, SN60WF. Setting: 19 investigational sites in 4 countries: Australia, Canada, Spain, and the United Kingdom. Design: Prospective, randomized, parallel-group, controlled, assessor- and patient-masked clinical study. Methods: Participants aged ≥22 years with bilateral cataracts were randomized to DFT015 or SN60WF in a 5:4 ratio and masked until final postoperative follow-up at month 6. The primary effectiveness objective was superiority of DFT015 over SN60WF in mean monocular photopic distance-corrected intermediate visual acuity (DCIVA) at month 3. Secondary effectiveness objectives included noninferiority of DFT015 to SN60WF in mean monocular photopic corrected distance visual acuity (CDVA) and superiority in the mean monocular photopic distance-corrected near visual acuity (DCNVA) at month 3. Visual disturbances were assessed at month 6. Results: 282 patients were randomized to DFT015 (n = 159) or SN60WF (n = 123). All effectiveness objectives were achieved at month 3 in first eyes. For monocular photopic results in first eyes, DFT015 demonstrated superior mean DCIVA (least squares means of −0.139 logMAR in favor of DFT015, P < .001), noninferior mean CDVA (97.5% upper confidence limit [UCL] of the difference was <0.1 logMAR) and superior mean DCNVA (95% UCL of the difference was <0.0 logMAR) compared with SN60WF at month 6. DFT015 exhibited a similar visual disturbance profile to that of SN60WF. Conclusions: DFT015 provided superior intermediate and near vision and a similar visual disturbance profile compared with an aspheric monofocal IOL.
Geographic atrophy (GA) secondary to age-related macular degeneration is a common cause of blindness worldwide. Given the recent approval of the first therapy for GA, pegcetacoplan, we critically appraise methodological aspects of the phase 3 clinical trials published so far in this disease in relation to their design, analysis and interpretation. We reviewed some of the key attributes of all phase 3 clinical trials in GA available in the main public registry of clinical trials as of 20 May 2023. The topics discussed included types of endpoints, eligibility criteria, p-value and effect size, study power and sample size, the intention to treat principle, missing data, consistency of results, efficacy–safety balance and application of results. Five phase 3 clinical trials have reported results, either partially or completely: GATHER1, DERBY/OAKS, CHROMA/SPECTRI, SEATTLE and GATE. Although there are many similarities between these trials in terms of endpoints or broad eligibility criteria, they differ in several aspects (metric of the primary endpoint, sample size, type of adverse events, etc.) that can influence the results, which are discussed. Readers should understand key methodological aspects of clinical trials to improve their interpretation. On the other hand, authors should adhere to clinical trial reporting guidelines to communicate what was done and how it was done.
Background/Objectives: This study aimed to characterize the visual performance in patients with bilateral cataracts and a unilateral epiretinal membrane (ERM) undergoing cataract surgery with non-diffractive extended depth of focus (EDoF) intraocular lens (IOL) placement in both eyes and phacovitrectomy in the eye with ERM. Methods: This was a prospective, descriptive, single-arm study. Visual outcomes were measured in monocular and binocular conditions in patients with bilateral cataracts and unilateral ERM stages 2 or 3 implanted with an EDoF IOL. At 6 months, visual acuity (uncorrected and corrected at different distances and contrast levels), contrast sensitivity, and visual disturbances assessed using a Light Distortion Analyzer were determined. Results: We included 22 patients (50% females, mean age of 71.4 ± 5.8 years). Mean monocular best-corrected visual acuities at 100% contrast were 0.07 ± 0.09, 0.23 ± 0.10, and 0.48 ± 0.14 logMAR for eyes with ERM, and 0.02 ± 0.08, 0.19 ± 0.11, and 0.41 ± 0.18 logMAR for fellow eyes for far, intermediate, and near distance vision, respectively. No differences were observed in visual outcomes, contrast sensitivity, or visual disturbances between ERM and non-ERM eyes, except for near distance. No unexpected adverse events were observed. Conclusions: Non-diffractive EDoF IOL can be considered in patients with cataracts and stage 2 or 3 ERM pursuing spectacle independence.
13 July 2021 in Journal of Cataract & Refractive Surgery Online Case Reports
A case of a 44-year-old man undergoing cataract surgery because of ocular trauma in his right eye in which a nondiffractive continuous extended range-of-vision intraocular lens (IOL) was implanted is described. Uneventful bilateral myopic laser in situ keratomileusis correction had been performed 13 years before (oblate corneal profile). At 3 months postoperatively, uncorrected distance, intermediate, and near visual acuities were 0.10, 0.10, and 0.20 logMAR, respectively. An improvement was also observed in most of the subscales of the Visual Functioning Questionnaire-25, with the largest improvement in the subscales driving, distance activities, and general vision. Light distortion indices of 10.19% and 3.82% were found in the right and left eyes, respectively. This case shows that the unilateral implantation of this type of IOL can be a good solution in eyes with previous myopic corneal laser refractive surgery when monocular cataract surgery is needed, allowing a successful binocular visual restoration.
Background/Objectives: This study’s aim was to compare the precision, agreement, and accuracy in axial length (AL) measurements of Argos® (Alcon Healthcare, US) and Eyestar 900® (Haag-Streit, Switzerland) swept-source optical coherence tomography (SS-OCT) biometers. Methods: We performed a prospective evaluation of two diagnostic devices. Three consecutive measurements of AL with the Argos® and the Eyestar® 900 SS-OCT biometers were conducted in random order in eyes undergoing cataract surgery in Barcelona, Spain. The main endpoint was the median difference in AL between devices. Secondary endpoints included agreement on Bland–Altman plots and 95% limits of agreement (LoAs), repeatability as measured within-subject standard deviation (SW), percent of failed AL measurements, percent of eyes within ±0.50 D and ±1.00 D one month after surgery, and median and mean prediction error. Results: We included 107 eyes of 107 patients (60.8% females, mean age of 73.1 years). The median difference in AL (Argos®-Eyestar 900®) was −0.01 mm (interquartile range [IQR], 0.06), p = 0.01. The 95% LoAs were −0.11 to +0.08 mm, with a trend towards less extreme measurements with Argos® for very short and long eyes. The median (IQR) Sw was 0.0058 (0.0058) and 0.0000 (0.0058) for Argos® and Eyestar 900®, respectively. There were no failed AL measurements with either device (0%, 95% CI = 0% to 3.4%). Overall, 96.1% of eyes were within ±0.50 D and 100% were within ±1.00 D. Conclusions: Argos® and Eyestar 900® provided statistically different but clinically negligible differences in AL. However, they are not interchangeable in very long or short eyes, due to the different principles used to determine AL.
Background/Objectives: The role of the vitreous in the effective lens position (ELP) is controversial in patients undergoing phacovitrectomy. The aim of this study was to compare the change in aqueous depth (AD), a surrogate of the ELP, in non-vitrectomized and vitrectomized fellow eyes. Methods: Post-hoc analysis of a prospective study conducted in OMIQ facilities (Barcelona, Spain) between 2021 and 2023. Patients with bilateral cataracts and a unilateral grade 2/3 epiretinal membrane underwent phacoemulsification in one eye and phacovitrectomy without endotamponade in the fellow eye. All eyes were implanted with an extended depth-of-focus intraocular lens after power calculation using the same biometer, technicians, formula, and surgeon. We compared the change in AD (mm and percentage) from baseline, and the role of vitrectomy without endotamponade on AD with a mixed-effects models. Results: We included 40 eyes (20 patients) with a mean age of 71.6 years, with 55% females. The mean change in AD was +1.51 (vitrectomized) and +1.42 mm (non-vitrectomized eyes), p = 0.33. The percent of change in AD was not different between groups (p ≥ 0.38) and phacovitrectomy had no effect on the change in AD on mixed-effects models (p > 0.10). Conclusions: The absence of the vitreous had a minimal influence on AD in these patients undergoing standard phacoemulsification or phacovitrectomy.